Abivax SA Sponsored ADR $ABVX Holdings Raised by Aberdeen Group plc

Key Points

• Aberdeen Group plc increased its holdings in Abivax SA by 67.5% in Q1, owning approximately 1.12% of the company's stock valued at $4,441,000.
• Several hedge funds have also significantly raised their stakes in Abivax, with a collective 47.91% of the stock owned by institutional investors.
• Analysts have raised their price targets for Abivax shares, with targets now ranging from $74.00 to $112.00, reflecting an overall positive sentiment towards the stock.

Aberdeen Group plc raised its stake in shares of Abivax SA Sponsored ADR (NASDAQ:ABVX - Free Report) by 67.5% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 710,516 shares of the company's stock after buying an additional 286,335 shares during the period. Aberdeen Group plc owned about 1.12% of Abivax worth $4,441,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the stock. Bank of America Corp DE raised its holdings in shares of Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after acquiring an additional 1,990 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Abivax during the 4th quarter worth about $85,000. Guggenheim Capital LLC acquired a new stake in shares of Abivax during the 4th quarter valued at about $92,000. Stonepine Capital Management LLC bought a new stake in shares of Abivax in the 4th quarter valued at approximately $110,000. Finally, GAMMA Investing LLC grew its stake in shares of Abivax by 373.6% in the 1st quarter. GAMMA Investing LLC now owns 18,831 shares of the company's stock valued at $118,000 after buying an additional 14,855 shares in the last quarter. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Price Performance

ABVX opened at $71.89 on Thursday. The business has a 50 day moving average of $33.93 and a 200-day moving average of $16.06. The company has a debt-to-equity ratio of 1.29, a current ratio of 1.25 and a quick ratio of 1.25. Abivax SA Sponsored ADR has a 1-year low of $4.77 and a 1-year high of $75.51.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Guggenheim lifted their target price on shares of Abivax from $50.00 to $101.00 and gave the company a "buy" rating in a research note on Wednesday, July 23rd. Piper Sandler lifted their price objective on shares of Abivax from $70.00 to $112.00 and gave the company an "overweight" rating in a research note on Tuesday, July 29th. Leerink Partners set a $74.00 price objective on shares of Abivax and gave the stock an "outperform" rating in a report on Wednesday, July 23rd. Citigroup restated a "market outperform" rating on shares of Abivax in a report on Friday, July 18th. Finally, Lifesci Capital upped their price target on Abivax from $45.00 to $101.00 and gave the stock an "outperform" rating in a research note on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the stock. According to data from MarketBeat.com, Abivax has an average rating of "Buy" and an average target price of $92.33.

Abivax Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.